Although still controversial, the idea of cholesterol as a key regulator of the amyloidogenic pathway of Amyloid Precursor Protein (APP) and Aβ formation is gaining the attention of research since statins, a drug widely used to lower peripheral cholesterol levels by inhibiting de novo synthesis, have been reported to lower the prevalence of AD for subjects taking this drug [12]. The gene discussed is APP; the disease is Alzheimer disease.